Cost-Effectiveness of Oxaliplatin in the Adjuvant Treatment of Colon Cancer in Canada

Abstract

With an incremental cost of CA$24,104 per QALY gained, FOLFOX is a cost-effective adjuvant treatment for stage iii colon cancer. Compared with 5fu/lv alone, this regimen offers better clinical outcomes and provides good value for money.